tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jan 21;10(2):162.
doi: 10.3390/vaccines10020162.
Selection of an Optimal Recombinant Egyptian H9N2 Avian Influenza Vaccine Strain for Poultry with High Antigenicity and Safety
Se-Hee An[SUP] 1 2 [/SUP], Seung-Eun Son[SUP] 1 [/SUP], Jin-Ha Song[SUP] 1 [/SUP], Seung-Min Hong[SUP] 1 2 [/SUP], Chung-Young Lee[SUP] 3 [/SUP], Nak-Hyung Lee[SUP] 4 [/SUP], Young-Ju Jeong[SUP] 4 [/SUP], Jun-Gu Choi[SUP] 5 [/SUP], Youn-Jeong Lee[SUP] 5 [/SUP], Hyun-Mi Kang[SUP] 5 [/SUP], Kang-Seuk Choi[SUP] 1 2 [/SUP], Hyuk-Joon Kwon[SUP] 2 6 7 [/SUP]
Affiliations
Abstract
For the development of an optimized Egyptian H9N2 vaccine candidate virus for poultry, various recombinant Egyptian H9N2 viruses generated by a PR8-based reverse genetics system were compared in terms of their productivity and biosafety since Egyptian H9N2 avian influenza viruses already possess mammalian pathogenicity-related mutations in the hemagglutinin (HA), neuraminidase (NA), and PB2 genes. The Egyptian HA and NA genes were more compatible with PR8 than with H9N2 AIV (01310) internal genes, and the 01310-derived recombinant H9N2 strains acquired the L226Q reverse mutation in HA after passages in eggs. Additionally, the introduction of a strong promoter at the 3'-ends of PB2 and PB1 genes induced an additional mutation of P221S. When recombinant Egyptian H9N2 viruses with intact or reverse mutated HA (L226Q and P221S) and NA (prototypic 2SBS) were compared, the virus with HA and NA mutations had high productivity in ECES but was lower in antigenicity when used as an inactivated vaccine due to its high binding affinity into non-specific inhibitors in eggs. Finally, we substituted the PB2 gene of PR8 with 01310 to remove the replication ability in mammalian hosts and successfully generated the best recombinant vaccine candidate in terms of immunogenicity, antigenicity, and biosafety.
Keywords: H9N2; avian influenza virus; genetic evolution; mammalian non-pathogenicity; recombinant vaccine strain.
. 2022 Jan 21;10(2):162.
doi: 10.3390/vaccines10020162.
Selection of an Optimal Recombinant Egyptian H9N2 Avian Influenza Vaccine Strain for Poultry with High Antigenicity and Safety
Se-Hee An[SUP] 1 2 [/SUP], Seung-Eun Son[SUP] 1 [/SUP], Jin-Ha Song[SUP] 1 [/SUP], Seung-Min Hong[SUP] 1 2 [/SUP], Chung-Young Lee[SUP] 3 [/SUP], Nak-Hyung Lee[SUP] 4 [/SUP], Young-Ju Jeong[SUP] 4 [/SUP], Jun-Gu Choi[SUP] 5 [/SUP], Youn-Jeong Lee[SUP] 5 [/SUP], Hyun-Mi Kang[SUP] 5 [/SUP], Kang-Seuk Choi[SUP] 1 2 [/SUP], Hyuk-Joon Kwon[SUP] 2 6 7 [/SUP]
Affiliations
- PMID: 35214621
- PMCID: PMC8876024
- DOI: 10.3390/vaccines10020162
Abstract
For the development of an optimized Egyptian H9N2 vaccine candidate virus for poultry, various recombinant Egyptian H9N2 viruses generated by a PR8-based reverse genetics system were compared in terms of their productivity and biosafety since Egyptian H9N2 avian influenza viruses already possess mammalian pathogenicity-related mutations in the hemagglutinin (HA), neuraminidase (NA), and PB2 genes. The Egyptian HA and NA genes were more compatible with PR8 than with H9N2 AIV (01310) internal genes, and the 01310-derived recombinant H9N2 strains acquired the L226Q reverse mutation in HA after passages in eggs. Additionally, the introduction of a strong promoter at the 3'-ends of PB2 and PB1 genes induced an additional mutation of P221S. When recombinant Egyptian H9N2 viruses with intact or reverse mutated HA (L226Q and P221S) and NA (prototypic 2SBS) were compared, the virus with HA and NA mutations had high productivity in ECES but was lower in antigenicity when used as an inactivated vaccine due to its high binding affinity into non-specific inhibitors in eggs. Finally, we substituted the PB2 gene of PR8 with 01310 to remove the replication ability in mammalian hosts and successfully generated the best recombinant vaccine candidate in terms of immunogenicity, antigenicity, and biosafety.
Keywords: H9N2; avian influenza virus; genetic evolution; mammalian non-pathogenicity; recombinant vaccine strain.